Mayne Pharma Group Limited
Research Mayne Pharma Group Limited (MYX.AX) on Bullrun: market cap AUD 206.37M, P/E 8.1. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerMYX.AX
- ExchangeAU
- CountryAustralia
- SectorHealthcare
- IndustryMedical Distribution
- CurrencyAUD
- Market capAUD 206.37M
- P/E8.1
- Financial periodFY2026
- RevenueAUD 378.37M
- Revenue growth-2.5%
- Net incomeAUD 24.47M
- Free cash flowAUD 10.55M
- Gross margin64.2%
Valuation Snapshot
latest market cap is AUD 206.37M; P/E is 8.1.
Peer valuation comparison
Latest P/E is 8.13x versus a Healthcare sector median of 21.74x (62.6% below).
Latest P/E is 8.13x versus a Australia median of 14.68x (44.6% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2026 | AUD 378.37M | AUD 24.47M | AUD 10.55M | 64.2% | 0.23 | AUD 80.00M | AUD 43.20M | AUD 390.94M |
| FY2024 | AUD 387.90M | -AUD 174.23M | -AUD 36.16M | 56.3% | -2.12 | AUD 110.07M | AUD 38.82M | AUD 454.19M |
| FY2023 | AUD 182.39M | AUD 117.25M | -AUD 262.30M | 45.1% | 1.42 | AUD 92.62M | AUD 47.51M | AUD 634.36M |
| FY2022 | AUD 423.92M | -AUD 263.34M | -AUD 19.06M | 40.1% | -3.2 | AUD 96.67M | AUD 413.67M | AUD 564.77M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-17 | AUD 206.37M | 8.1 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 AUD.
| Year | Dividends/share |
|---|---|
| FY2023 | 0.54 AUD |
About Mayne Pharma Group Limited
Mayne Pharma Group Limited, a specialty pharmaceutical company, focuses on the commercialization of women's health and dermatology pharmaceuticals in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. It operates through three segments: Women's Health, Dermatology, and International. The company provides oral drug delivery systems, as well as contract development and manufacturing services to third party customers.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Mayne Pharma Group Limited's market cap?
Mayne Pharma Group Limited's market capitalization is AUD 206.37M.
What is Mayne Pharma Group Limited's P/E ratio?
Mayne Pharma Group Limited's price-to-earnings (P/E) ratio is 8.1.
What does Mayne Pharma Group Limited do?
Mayne Pharma Group Limited, a specialty pharmaceutical company, focuses on the commercialization of women's health and dermatology pharmaceuticals in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. It operates through three segments: Women's Health, Dermatology, and International. The company provides oral drug delivery systems, as well as contract development and manufacturing services to third party customers. It also distributes specialty pharmaceutical products in the dermatology, women's health, and infectious disease areas.